[{"id":1184654033,"body":"CPIC phenytoin guideline","history":[{"id":1446907026,"date":"2015-10-21T12:19:46.437-07:00","type":"approve"}],"literature":[{"@id":"https://www.pharmgkb.org/data/literature/25099164","@context":"https://www.pharmgkb.org/data/literature.jsonld","id":15080841,"resourceId":"25099164","title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing","authors":["Caudle Kelly E","Rettie Allan E","Whirl-Carrillo Michelle","Smith Lisa H","Mintzer Scott E","Lee Ming Ta Michael","Klein Teri E","Callaghan J Thomas"],"crossReferenceUrl":"http://www.ncbi.nlm.nih.gov/pubmed/25099164","journal":"Clinical pharmacology and therapeutics","month":8,"pubDate":"2014-08-01T00:00:00-07:00","type":"article","year":2014}],"sources":["CPIC"],"targets":[{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166122806","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166122806","name":"CPIC Dosing Guideline for phenytoin and CYP2C9,HLA-B","version":5}],"type":"publicationSet","valid":true,"version":1},{"id":1184683072,"body":"CPIC codeine guideline","literature":[{"@id":"https://www.pharmgkb.org/data/literature/24458010","@context":"https://www.pharmgkb.org/data/literature.jsonld","id":15069654,"resourceId":"24458010","title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 Update","authors":["Crews Kristine R","Gaedigk Andrea","Dunnenberger Henry M","Leeder J Steve","Klein Teri E","Caudle Kelly E","Haidar Cyrine E","Shen Danny D","Callaghan John T","Sadhasivam Senthilkumar","Prows Cynthia A","Kharasch Evan D","Skaar Todd C"],"crossReferenceUrl":"http://www.ncbi.nlm.nih.gov/pubmed/24458010","journal":"Clinical pharmacology and therapeutics","month":1,"pubDate":"2014-01-01T00:00:00-08:00","type":"article","year":2014},{"@id":"https://www.pharmgkb.org/data/literature/22205192","@context":"https://www.pharmgkb.org/data/literature.jsonld","id":14821790,"resourceId":"22205192","title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype","authors":["Crews K R","Gaedigk A","Dunnenberger H M","Klein T E","Shen D D","Callaghan J T","Kharasch E D","Skaar T C"],"crossReferenceUrl":"http://www.ncbi.nlm.nih.gov/pubmed/22205192","journal":"Clinical pharmacology and therapeutics","month":12,"pubDate":"2011-12-01T00:00:00-08:00","type":"article","year":2011}],"sources":["CPIC"],"targets":[{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166104996","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166104996","name":"CPIC Dosing Guideline for codeine and CYP2D6","version":9}],"type":"publicationSet","valid":true},{"id":1184683073,"body":"CPIC PEG interferon-alpha guideline","literature":[{"@id":"https://www.pharmgkb.org/data/literature/24096968","@context":"https://www.pharmgkb.org/data/literature.jsonld","id":15064565,"resourceId":"24096968","title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and peginterferon alpha based regimens","authors":["Muir Andrew J","Gong Li","Johnson Samuel G","Michael Lee Ming Ta","Williams Marc S","Klein Teri E","Caudle Kelly E","Nelson David R"],"crossReferenceUrl":"http://www.ncbi.nlm.nih.gov/pubmed/24096968","journal":"Clinical pharmacology and therapeutics","month":10,"pubDate":"2013-10-01T00:00:00-07:00","type":"article","year":2013}],"sources":["CPIC"],"targets":[{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166110235","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166110235","name":"CPIC Dosing Guideline for boceprevir,peginterferon alfa-2a,peginterferon alfa-2b,ribavirin,telaprevir and IFNL3","version":6}],"type":"publicationSet","valid":true},{"id":1184683074,"body":"CPIC ivacaftor guideline","literature":[{"@id":"https://www.pharmgkb.org/data/literature/24598717","@context":"https://www.pharmgkb.org/data/literature.jsonld","id":15071319,"resourceId":"24598717","title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype","authors":["Clancy John P","Johnson Samuel G","Yee Sook Wah","McDonagh Ellen M","Caudle Kelly E","Klein Teri E","Cannavo Matthew","Giacomini Kathleen M"],"crossReferenceUrl":"http://www.ncbi.nlm.nih.gov/pubmed/24598717","journal":"Clinical pharmacology and therapeutics","month":3,"pubDate":"2014-03-01T00:00:00-08:00","type":"article","year":2014}],"sources":["CPIC"],"targets":[{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166114461","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166114461","name":"CPIC Dosing Guideline for ivacaftor and CFTR","version":7}],"type":"publicationSet","valid":true},{"id":1184683075,"body":"CPIC rasburicase guideline","literature":[{"@id":"https://www.pharmgkb.org/data/literature/24787449","@context":"https://www.pharmgkb.org/data/literature.jsonld","id":15074661,"resourceId":"24787449","title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the context of G6PD Deficiency Genotype","authors":["Relling Mary V","McDonagh Ellen M","Chang Tamara","Caudle Kelly E","McLeod Howard L","Haidar Cyrine E","Klein Teri","Luzzatto Lucio"],"crossReferenceUrl":"http://www.ncbi.nlm.nih.gov/pubmed/24787449","journal":"Clinical pharmacology and therapeutics","month":5,"pubDate":"2014-05-01T00:00:00-07:00","type":"article","year":2014}],"sources":["CPIC"],"targets":[{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166119846","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166119846","name":"CPIC Dosing Guideline for rasburicase and G6PD","version":8}],"type":"publicationSet","valid":true},{"id":1184683076,"body":"CPIC TCAs guideline","literature":[{"@id":"https://www.pharmgkb.org/data/literature/23486447","@context":"https://www.pharmgkb.org/data/literature.jsonld","id":15051926,"resourceId":"23486447","title":"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants","authors":["Hicks J K","Swen J J","Thorn C F","Sangkuhl K","Kharasch E D","Ellingrod V L","Skaar T C","Müller D J","Gaedigk A","Stingl J C"],"crossReferenceUrl":"http://www.ncbi.nlm.nih.gov/pubmed/23486447","journal":"Clinical pharmacology and therapeutics","month":1,"pubDate":"2013-01-01T00:00:00-08:00","type":"article","year":2013}],"sources":["CPIC"],"targets":[{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166105006","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166105006","name":"CPIC Dosing Guideline for amitriptyline and CYP2C19,CYP2D6","version":6},{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166105007","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166105007","name":"CPIC Dosing Guideline for clomipramine and CYP2C19,CYP2D6","version":6},{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166105002","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166105002","name":"CPIC Dosing Guideline for desipramine and CYP2D6","version":6},{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166105000","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166105000","name":"CPIC Dosing Guideline for doxepin and CYP2C19,CYP2D6","version":6},{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166104999","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166104999","name":"CPIC Dosing Guideline for imipramine and CYP2C19,CYP2D6","version":6},{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166104998","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166104998","name":"CPIC Dosing Guideline for nortriptyline and CYP2D6","version":8},{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166105001","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166105001","name":"CPIC Dosing Guideline for trimipramine and CYP2C19,CYP2D6","version":8}],"type":"publicationSet","valid":true,"version":1},{"id":1184683077,"body":"CPIC simvastatin guideline","literature":[{"@id":"https://www.pharmgkb.org/data/literature/24918167","@context":"https://www.pharmgkb.org/data/literature.jsonld","id":15077441,"resourceId":"24918167","title":"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update","authors":["Ramsey Laura B","Johnson Samuel G","Caudle Kelly E","Haidar Cyrine E","Voora Deepak","Wilke Russell A","Maxwell Whitney D","McLeod Howard L","Krauss Ronald M","Roden Dan M","Feng Qiping","Cooper-DeHoff Rhonda M","Gong Li","Klein Teri E","Wadelius Mia","Niemi Mikko"],"crossReferenceUrl":"http://www.ncbi.nlm.nih.gov/pubmed/24918167","journal":"Clinical pharmacology and therapeutics","month":6,"pubDate":"2014-06-01T00:00:00-07:00","type":"article","year":2014},{"@id":"https://www.pharmgkb.org/data/literature/22617227","@context":"https://www.pharmgkb.org/data/literature.jsonld","id":15013653,"resourceId":"22617227","title":"The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy","authors":["Wilke R A","Ramsey L B","Johnson S G","Maxwell W D","McLeod H L","Voora D","Krauss R M","Roden D M","Feng Q","Cooper-Dehoff R M","Gong L","Klein T E","Wadelius M","Niemi M"],"crossReferenceUrl":"http://www.ncbi.nlm.nih.gov/pubmed/22617227","journal":"Clinical pharmacology and therapeutics","month":5,"pubDate":"2012-05-01T00:00:00-07:00","type":"article","year":2012}],"sources":["CPIC"],"targets":[{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166105005","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166105005","name":"CPIC Dosing Guideline for simvastatin and SLCO1B1","version":8}],"type":"publicationSet","valid":true},{"id":1184683078,"body":"CPIC clopidogrel guideline","literature":[{"@id":"https://www.pharmgkb.org/data/literature/23698643","@context":"https://www.pharmgkb.org/data/literature.jsonld","id":15058235,"resourceId":"23698643","title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy: 2013 Update","authors":["Scott Stuart A","Sangkuhl Katrin","Stein C Michael","Hulot Jean-Sébastien","Mega Jessica L","Roden Dan M","Klein Teri E","Sabatine Marc S","Johnson Julie A","Shuldiner Alan R"],"crossReferenceUrl":"http://www.ncbi.nlm.nih.gov/pubmed/23698643","journal":"Clinical pharmacology and therapeutics","month":5,"pubDate":"2013-05-01T00:00:00-07:00","type":"article","year":2013},{"@id":"https://www.pharmgkb.org/data/literature/21716271","@context":"https://www.pharmgkb.org/data/literature.jsonld","id":8231172,"resourceId":"21716271","title":"Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy","authors":["Scott S A","Sangkuhl K","Gardner E E","Stein C M","Hulot J-S","Johnson J A","Roden D M","Klein T E","Shuldiner A R"],"crossReferenceUrl":"http://www.ncbi.nlm.nih.gov/pubmed/21716271","journal":"Clinical pharmacology and therapeutics","month":6,"pubDate":"2011-06-01T00:00:00-07:00","type":"article","year":2011}],"sources":["CPIC"],"targets":[{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166104948","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166104948","name":"CPIC Dosing Guideline for clopidogrel and CYP2C19","version":7}],"type":"publicationSet","valid":true},{"id":1184683079,"body":"CPIC warfarin guideline","literature":[{"@id":"https://www.pharmgkb.org/data/literature/21900891","@context":"https://www.pharmgkb.org/data/literature.jsonld","id":8560040,"resourceId":"21900891","title":"Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing","authors":["Johnson J A","Gong L","Whirl-Carrillo M","Gage B F","Scott S A","Stein C M","Anderson J L","Kimmel S E","Lee M T M","Pirmohamed M","Wadelius M","Klein T E","Altman R B"],"crossReferenceUrl":"http://www.ncbi.nlm.nih.gov/pubmed/21900891","journal":"Clinical pharmacology and therapeutics","month":9,"pubDate":"2011-09-01T00:00:00-07:00","type":"article","year":2011}],"sources":["CPIC"],"targets":[{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166104949","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166104949","name":"CPIC Dosing Guideline for warfarin and CYP2C9,VKORC1","version":9}],"type":"publicationSet","valid":true},{"id":1184683080,"body":"CPIC fluoropyrimidine guideline","literature":[{"@id":"https://www.pharmgkb.org/data/literature/23988873","@context":"https://www.pharmgkb.org/data/literature.jsonld","id":15062135,"resourceId":"23988873","title":"Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing","authors":["Caudle Kelly E","Thorn Caroline F","Klein Teri E","Swen Jesse J","McLeod Howard L","Diasio Robert B","Schwab Matthias"],"crossReferenceUrl":"http://www.ncbi.nlm.nih.gov/pubmed/23988873","journal":"Clinical pharmacology and therapeutics","month":8,"pubDate":"2013-08-01T00:00:00-07:00","type":"article","year":2013}],"sources":["CPIC"],"targets":[{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166109594","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166109594","name":"CPIC Dosing Guideline for capecitabine and DPYD","version":10},{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166122686","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166122686","name":"CPIC Dosing Guideline for fluorouracil and DPYD","version":2},{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166122687","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166122687","name":"CPIC Dosing Guideline for tegafur and DPYD","version":3}],"type":"publicationSet","valid":true},{"id":1184683081,"body":"CPIC abacavir guideline","literature":[{"@id":"https://www.pharmgkb.org/data/literature/24561393","@context":"https://www.pharmgkb.org/data/literature.jsonld","id":15070904,"resourceId":"24561393","title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update","authors":["Martin Michael A","Hoffman James M","Freimuth Robert R","Klein Teri E","Dong Betty J","Pirmohamed Munir","Hicks J Kevin","Wilkinson Mark R","Haas David W","Kroetz Deanna L"],"crossReferenceUrl":"http://www.ncbi.nlm.nih.gov/pubmed/24561393","journal":"Clinical pharmacology and therapeutics","month":2,"pubDate":"2014-02-01T00:00:00-08:00","type":"article","year":2014},{"@id":"https://www.pharmgkb.org/data/literature/22378157","@context":"https://www.pharmgkb.org/data/literature.jsonld","id":14962778,"resourceId":"22378157","title":"Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing","authors":["Martin M A","Klein T E","Dong B J","Pirmohamed M","Haas D W","Kroetz D L"],"crossReferenceUrl":"http://www.ncbi.nlm.nih.gov/pubmed/22378157","journal":"Clinical pharmacology and therapeutics","month":2,"pubDate":"2012-02-01T00:00:00-08:00","type":"article","year":2012}],"sources":["CPIC"],"targets":[{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166104997","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166104997","name":"CPIC Dosing Guideline for abacavir and HLA-B","version":9}],"type":"publicationSet","valid":true},{"id":1184683082,"body":"CPIC carbamazepine guideline","literature":[{"@id":"https://www.pharmgkb.org/data/literature/23695185","@context":"https://www.pharmgkb.org/data/literature.jsonld","id":15058356,"resourceId":"23695185","title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Carbamazepine Dosing","authors":["Leckband Susan G","Kelsoe John R","Dunnenberger H Mark","George Alfred L","Tran Eric","Berger Reisel","Müller Daniel J","Whirl-Carrillo Michelle","Caudle Kelly E","Pirmohamed Munir"],"crossReferenceUrl":"http://www.ncbi.nlm.nih.gov/pubmed/23695185","journal":"Clinical pharmacology and therapeutics","month":5,"pubDate":"2013-05-01T00:00:00-07:00","type":"article","year":2013}],"sources":["CPIC"],"targets":[{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166105008","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166105008","name":"CPIC Dosing Guideline for carbamazepine and HLA-B","version":5}],"type":"publicationSet","valid":true},{"id":1184683083,"body":"CPIC allopurinol guideline","literature":[{"@id":"https://www.pharmgkb.org/data/literature/23232549","@context":"https://www.pharmgkb.org/data/literature.jsonld","id":15033427,"resourceId":"23232549","title":"Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing","authors":["Hershfield M S","Callaghan J T","Tassaneeyakul W","Mushiroda T","Thorn C F","Klein T E","Lee M T M"],"crossReferenceUrl":"http://www.ncbi.nlm.nih.gov/pubmed/23232549","journal":"Clinical pharmacology and therapeutics","month":10,"pubDate":"2012-10-01T00:00:00-07:00","type":"article","year":2012}],"sources":["CPIC"],"targets":[{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166105003","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166105003","name":"CPIC Dosing Guideline for allopurinol and HLA-B","version":9}],"type":"publicationSet","valid":true},{"id":1184683084,"body":"CPIC thiopurine guideline","literature":[{"@id":"https://www.pharmgkb.org/data/literature/23422873","@context":"https://www.pharmgkb.org/data/literature.jsonld","id":15051187,"resourceId":"23422873","title":"Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update","authors":["Relling M V","Gardner E E","Sandborn W J","Schmiegelow K","Pui C-H","Yee S W","Stein C M","Carrillo M","Evans W E","Hicks J K","Schwab M","Klein T E"],"crossReferenceUrl":"http://www.ncbi.nlm.nih.gov/pubmed/23422873","journal":"Clinical pharmacology and therapeutics","month":1,"pubDate":"2013-01-01T00:00:00-08:00","type":"article","year":2013},{"@id":"https://www.pharmgkb.org/data/literature/21270794","@context":"https://www.pharmgkb.org/data/literature.jsonld","id":6690400,"resourceId":"21270794","title":"Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing","authors":["Relling M V","Gardner E E","Sandborn W J","Schmiegelow K","Pui C-H","Yee S W","Stein C M","Carrillo M","Evans W E","Klein T E"],"crossReferenceUrl":"http://www.ncbi.nlm.nih.gov/pubmed/21270794","journal":"Clinical pharmacology and therapeutics","month":3,"page":"387-91","pubDate":"2011-03-01T00:00:00-08:00","type":"article","volume":"89","year":2011}],"sources":["CPIC"],"targets":[{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166104933","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166104933","name":"CPIC Dosing Guideline for azathioprine and TPMT","version":10},{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166104945","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166104945","name":"CPIC Dosing Guideline for mercaptopurine and TPMT","version":7},{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166104965","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166104965","name":"CPIC Dosing Guideline for thioguanine and TPMT","version":7}],"type":"publicationSet","valid":true},{"id":1444699035,"body":"CPIC tacrolimus guideline","literature":[{"@id":"https://www.pharmgkb.org/data/literature/25801146","@context":"https://www.pharmgkb.org/data/literature.jsonld","id":15087045,"resourceId":"25801146","title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","authors":["Birdwell Kelly A","Decker Brian","Barbarino Julia M","Peterson Josh F","Stein C Michael","Sadee Wolfgang","Wang Danxin","Vinks Alexander A","He Yijing","Swen Jesse J","Leeder J Steven","van Schaik R H N","Thummel Kenneth E","Klein Teri E","Caudle Kelly E","MacPhee Iain A M"],"crossReferenceUrl":"http://www.ncbi.nlm.nih.gov/pubmed/25801146","journal":"Clinical pharmacology and therapeutics","month":3,"pubDate":"2015-03-01T00:00:00-08:00","type":"article","year":2015}],"sources":["CPIC"],"targets":[{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166124619","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166124619","name":"CPIC Dosing Guideline for tacrolimus and CYP3A5","version":3}],"type":"publicationSet","valid":true},{"id":1444709215,"body":"CPIC SSRIs guideline","literature":[{"@id":"https://www.pharmgkb.org/data/literature/25974703","@context":"https://www.pharmgkb.org/data/literature.jsonld","id":15089021,"resourceId":"25974703","title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors","authors":["Hicks J Kevin","Bishop Jeffrey R","Sangkuhl Katrin","Müller Daniel J","Ji Yuan","Leckband Susan G","Leeder J Steven","Graham Rebecca L","Chiulli Dana L","LLerena Adrián","Skaar Todd C","Scott Stuart A","Stingl Julia C","Klein Teri E","Caudle Kelly E","Gaedigk Andrea"],"crossReferenceUrl":"http://www.ncbi.nlm.nih.gov/pubmed/25974703","journal":"Clinical pharmacology and therapeutics","month":5,"pubDate":"2015-05-01T00:00:00-07:00","type":"article","year":2015}],"sources":["CPIC"],"targets":[{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166127638","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166127638","name":"CPIC Dosing Guideline for citalopram,escitalopram and CYP2C19","version":4},{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166127637","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166127637","name":"CPIC Dosing Guideline for fluvoxamine and CYP2D6","version":4},{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166127636","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166127636","name":"CPIC Dosing Guideline for paroxetine and CYP2D6","version":4},{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166127639","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166127639","name":"CPIC Dosing Guideline for sertraline and CYP2C19","version":5}],"type":"publicationSet","valid":true,"version":2},{"id":1446902988,"body":"CPIC atazanavir guideline","history":[{"id":1446907027,"date":"2015-10-21T12:20:12.372-07:00","type":"approve"}],"literature":[{"@id":"https://www.pharmgkb.org/data/literature/26417955","@context":"https://www.pharmgkb.org/data/literature.jsonld","id":15093021,"resourceId":"26417955","title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing","authors":["Gammal Roseann S","Court Michael H","Haidar Cyrine E","Iwuchukwu Otito Frances","Gaur Aditya H","Alvarellos Maria","Guillemette Chantal","Lennox Jeffrey L","Whirl-Carrillo Michelle","Brummel Sean","Ratain Mark J","Klein Teri E","Schackman Bruce R","Caudle Kelly E","Haas David W"],"crossReferenceUrl":"http://www.ncbi.nlm.nih.gov/pubmed/26417955","journal":"Clinical pharmacology and therapeutics","month":9,"pubDate":"2015-09-01T00:00:00-07:00","type":"article","year":2015}],"sources":["CPIC"],"targets":[{"objCls":"Guideline","@id":"https://www.pharmgkb.org/data/guideline/PA166128738","@context":"https://www.pharmgkb.org/jsonld/guideline.jsonld","id":"PA166128738","name":"CPIC Dosing Guideline for atazanavir and UGT1A1","version":2}],"type":"publicationSet","valid":true,"version":1}]